Pharmagreen Biotech Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pharmagreen Biotech Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | ($875.5K) | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | ($4.53M) | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | ($2.48M) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($767.5K) | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | ($1.07M) | Dec 30, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | ($1.10M) | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | ($744.1K) | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | ($485.8K) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($642.2K) | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | ($748.7K) | Dec 30, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2019 | $4.0K | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | $7.6K | Dec 30, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | ($426.6K) | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | ($206.1K) | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | ($607.6K) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($317.8K) | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | ($785.5K) | Dec 30, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2019 | $196.1K | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | $251.3K | Dec 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $209.0K | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | $373.1K | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | $266.2K | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $630.3K | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | $449.4K | Dec 30, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $2.03M | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | $2.07M | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | $3.20M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | $1.46M | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | $1.84M | Dec 30, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | ($1.82M) | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | ($1.69M) | Jan 17, 2023 |
| FY2022 | Sep 30, 2020 | ($2.93M) | Jan 17, 2023 |
| FY2021 | Sep 30, 2019 | ($834.5K) | Dec 29, 2021 |
| FY2019 | Sep 30, 2018 | ($1.39M) | Dec 30, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | ($12.57M) | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | ($11.70M) | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | ($7.17M) | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | ($4.73M) | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | ($3.96M) | Dec 30, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $25.3K | Dec 29, 2021 |
| FY2021 | Sep 30, 2020 | $12.2K | Dec 29, 2021 |
| FY2021 | Sep 30, 2019 | $62.7K | Dec 29, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | 442.26M | Jan 17, 2023 |
| FY2022 | Sep 30, 2021 | 381.17M | Jan 17, 2023 |
| FY2021 | Sep 30, 2020 | 95.81M | Dec 29, 2021 |
| FY2020 | Sep 30, 2019 | 75.65M | Jan 8, 2021 |
| FY2019 | Sep 30, 2018 | 71.62M | Dec 30, 2019 |